Altimmune (NASDAQ:ALT) Receives “Buy” Rating from B. Riley

B. Riley reaffirmed their buy rating on shares of Altimmune (NASDAQ:ALT) in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a $20.00 price objective on the stock.

ALT has been the subject of several other research reports. The Goldman Sachs Group started coverage on Altimmune in a research report on Wednesday, January 24th. They issued a neutral rating and a $13.00 price objective for the company. HC Wainwright reissued a buy rating and issued a $15.00 target price on shares of Altimmune in a research note on Friday, December 1st.

Altimmune Price Performance

Shares of ALT opened at $10.18 on Thursday. The firm has a market cap of $546.97 million, a P/E ratio of -6.61 and a beta of 0.08. The stock has a 50 day simple moving average of $9.90 and a two-hundred day simple moving average of $6.71. Altimmune has a 1 year low of $2.09 and a 1 year high of $14.84.

Hedge Funds Weigh In On Altimmune

Institutional investors have recently added to or reduced their stakes in the company. FNY Investment Advisers LLC purchased a new position in Altimmune during the 4th quarter valued at approximately $35,000. Russell Investments Group Ltd. grew its holdings in Altimmune by 1,150.9% during the 4th quarter. Russell Investments Group Ltd. now owns 4,303 shares of the company’s stock valued at $48,000 after buying an additional 3,959 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in shares of Altimmune by 77.3% in the 2nd quarter. Osaic Holdings Inc. now owns 7,834 shares of the company’s stock worth $28,000 after purchasing an additional 3,416 shares during the period. Horizon Wealth Management LLC purchased a new position in shares of Altimmune in the 4th quarter worth approximately $112,000. Finally, Deuterium Capital Management LLC purchased a new position in shares of Altimmune in the 4th quarter worth approximately $112,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.